Disclaimer: The views, suggestions and opinions expressed here are the sole responsibility of the experts. No ZEX PR Wire journalist or Editor was involved in the writing and production of this article.

VANCOUVER, British Columbia, May 27, 2020 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company, announced it has executed an option agreement with an undisclosed publicly traded company for exclusive rights to BOLD-100 in South Korea. BOLD-100 is a first-in-class…